Kyverna Therapeutics, Inc.

KYTX

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 2,000,000Value: $18.8M

Deerfield's $18.8M entry into KYTX signals confidence in Kyverna's engineered T-cell platform, likely tied to upcoming clinical readouts for KT-001 in systemic lupus erythematosus (SLE)—a large autoimmune market with limited cell therapy options. The 2M-share position (~5-7% of float) suggests Deerfield sees near-term catalysts; key inflection points include Phase 2 data expected in 2024-2025. This vote of confidence from a specialized healthcare investor may attract institutional attention ahead of clinical milestones.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RDNT1 fund VTR1 fund PHVS1 fund PMVP1 fund ALHC1 fund ATRC1 fund BCRX1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: